Dr. Alastair Coupe is a member of Quotient Sciences' Scientific Advisory Board.

Dr. Coupe brings over 25 years of experience in pharmaceutical development, having held senior roles at Pfizer where he contributed to the development of numerous drug products and delivery technologies, including Tikosyn, Vfend, Sutent, and Lorviqua. His expertise spans a wide range of dosage forms, including oral, parenteral, inhalation, and pediatric formulations.

He has presented regulatory submissions to global agencies such as the EMA, FDA, and PMDA, and most recently led Pfizer’s efforts in addressing nitrosamine risk across its portfolio. Dr. Coupe also directed the cross-industry Innovate UK project focused on accelerating pediatric drug development and played a key role in securing funding for the UK’s National Formulation Centre.

Dr. Coupe earned his B.Pharm. and Ph.D. in Drug Delivery from the University of Nottingham. He holds honorary professorships at University College London and the University of Nottingham and serves on several academic and regulatory advisory boards, including the Academy of Pharmaceutical Sciences and the EPSRC Physical Sciences SAT.